Cambridge Investment Research Advisors
ADPT icon

Cambridge Investment Research Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,274
Closed -$213K – 3166
2021
Q3 		$213K Sell
6,274
-787
-11% -$28.5K ﹤0.01% 2758
2021
Q2 		$289K Buy
+7,061
New +$275K ﹤0.01% 2497

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Cambridge Investment Research Advisors's ADPT Position: Q4 2021 in Review

Cambridge Investment Research Advisors sold out of Adaptive Biotechnologies (ADPT) in Q4 2021, closing a stake of 6,274 shares — an estimated $213K sold.

Cambridge Investment Research Advisors first reported a position in ADPT in Q2 2021 and held it in 2 quarters. The position peaked at $289K in Q2 2021. 214 funds tracked by Wall St. Rank hold ADPT as of Q4 2021.

  • Cambridge Investment Research Advisors reported no remaining Adaptive Biotechnologies position as of Q4 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 6,274 Adaptive Biotechnologies shares in Q4 2021, an estimated $213K.
  • Cambridge Investment Research Advisors first reported a position in Adaptive Biotechnologies in Q2 2021 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's Adaptive Biotechnologies position peaked at $289K in Q2 2021.
  • 214 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.